Compare AMPY & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AMPY | IPHA |
|---|---|---|
| Founded | 2011 | 1999 |
| Country | United States | France |
| Employees | N/A | 163 |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 215.9M | 189.5M |
| IPO Year | 2011 | N/A |
| Metric | AMPY | IPHA |
|---|---|---|
| Price | $4.37 | $1.71 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $5.75 |
| AVG Volume (30 Days) | ★ 680.6K | 135.0K |
| Earning Date | 05-06-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 232.26 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $208,637,000.00 | N/A |
| Revenue This Year | N/A | $180.36 |
| Revenue Next Year | $23.83 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.11 | $1.18 |
| 52 Week High | $6.79 | $2.63 |
| Indicator | AMPY | IPHA |
|---|---|---|
| Relative Strength Index (RSI) | 28.40 | 51.54 |
| Support Level | $4.13 | $1.69 |
| Resistance Level | $4.92 | $1.84 |
| Average True Range (ATR) | 0.20 | 0.13 |
| MACD | -0.02 | -0.02 |
| Stochastic Oscillator | 3.02 | 9.90 |
Amplify Energy Corp is an independent oil and natural gas company engaged in the acquisition, development, exploitation, and production of oil and natural gas properties in the United States. The companies oil and natural gas properties are located in large, mature oil and natural gas reservoirs. The company assets consists of producing oil and natural gas properties located in Oklahoma, the Rockies, federal waters offshore Southern California, East Texas/North Louisiana and Eagle Ford.
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.